Medtronic stock reacts to sustained share price pressure

Medtronic (MDT) has come under pressure recently, with the stock down about 7% over the past month and roughly 20% over the past 3 months. This has prompted closer attention to its valuation and fundamentals.

At a share price of US$77.60, Medtronic's recent pressure adds to a year-to-date share price return that is down about 19%, while the 1-year total shareholder return is close to flat and the 5-year total shareholder return shows a sizeable decline.

If recent weakness in Medtronic has you reassessing your healthcare exposure, it might be a good time to see what else is moving in medical technology and 34 healthcare AI stocks.

With Medtronic’s share price under pressure, yet reporting annual revenue of US$35.5b and net income of US$4.6b, the key question is whether recent weakness leaves the stock undervalued or if the market is already pricing in future growth.

Most Popular Narrative: 18.3% Undervalued

With Medtronic last closing at $77.60 and the narrative fair value set at $95.00, the current price sits well below what this narrative suggests.

Financial Resilience: Strong cash flow ($5.8b operating cash flow FY2023) supports a dividend yield of ~3.4%, with 46 consecutive years of dividend increases. This is a track record few medtech peers can match. Attractive valuation metrics (P/E ~16x vs. industry avg. ~20x) suggest undervaluation.

Curious how that fair value comes together? The narrative leans heavily on steady revenue, firm margins and a profit profile that supports a higher valuation anchor.

Result: Fair Value of $95.00 (UNDERVALUED)

However, this narrative can crack if regulatory setbacks or continued pressure in the diabetes unit weighs on Medtronic’s earnings power and investor confidence.

Next Steps

If the mix of pressure and potential around Medtronic still feels mixed, act quickly and review the data directly before settling on a view. Start with 6 key rewards.

Looking for more investment ideas?

Do not stop at a single stock. Broaden your watchlist now so you are not relying on one story when there are many opportunities to compare.

• Target reliable cash returns by reviewing steady income candidates in the 10 dividend fortresses.
• Hunt for potential value opportunities that pair attractive pricing with quality fundamentals using the 46 high quality undervalued stocks.
• Focus on resilience first and check companies screened for stability and lower risk profiles through the 65 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.